|Articles|October 12, 2017

SGS and Bavarian Nordic to Develop a Challenge Model for Respiratory Syncytial Virus

SGS has collaborated with Bavarian Nordic to develop a novel and differentiated challenge model for respiratory syncytial virus. This partnership brings both expertise and a view of wanting to bring a life changing therapy to the market. This new model will assist with the advancement of a universal vaccine candidate designed to induce protective immune responses against both subtypes (A & B) of RSV.

Read the full release here.


Related to this article

© putilov_denis - © putilov_denis - stock.adobe.com
Real-time clinical trials require standardized digital data capture at the point of care through scaled eSource-EDC-EHR integration, but progress stalls because competing standards lack regulatory enforcement and one-off system integrations cannot scale beyond single studies without industry-wide alignment and legal clarity on data ownership.